Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to $5.9 million.

  • Abeona Therapeutics' Accounts Payables rose 11251.34% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 11251.34%. This contributed to the annual value of $3.4 million for FY2024, which is 8519.91% up from last year.
  • As of Q3 2025, Abeona Therapeutics' Accounts Payables stood at $5.9 million, which was up 11251.34% from $7.3 million recorded in Q2 2025.
  • Over the past 5 years, Abeona Therapeutics' Accounts Payables peaked at $7.3 million during Q2 2025, and registered a low of $1.5 million during Q2 2021.
  • For the 5-year period, Abeona Therapeutics' Accounts Payables averaged around $3.1 million, with its median value being $2.8 million (2024).
  • Per our database at Business Quant, Abeona Therapeutics' Accounts Payables tumbled by 5812.72% in 2022 and then soared by 13675.38% in 2025.
  • Quarter analysis of 5 years shows Abeona Therapeutics' Accounts Payables stood at $4.3 million in 2021, then tumbled by 58.13% to $1.8 million in 2022, then grew by 2.6% to $1.9 million in 2023, then soared by 85.2% to $3.4 million in 2024, then soared by 72.25% to $5.9 million in 2025.
  • Its Accounts Payables stands at $5.9 million for Q3 2025, versus $7.3 million for Q2 2025 and $5.0 million for Q1 2025.